Annals of Surgical Oncology

, Volume 21, Issue 2, pp 466–472 | Cite as

Isolated Hepatic Perfusion for Ocular Melanoma Metastasis: Registry Data Suggests a Survival Benefit

  • R. Olofsson
  • C. Cahlin
  • C. All-Ericsson
  • F. Hashimi
  • J. Mattsson
  • M. Rizell
  • P. Lindnér
Hepatobiliary Tumors

Abstract

Background

Uveal melanoma is the most common primary intraocular malignancy in adults. Despite successful control of the primary tumor, metastatic disease will ultimately develop in approximately 35 % of the patients, with the liver being the most common site for metastases. These metastases are generally refractory to systemic chemotherapy, and the median survival for patients with liver metastases is about 6 months. This phase II trial reports the experience of isolated hepatic perfusion (IHP) as a treatment option.

Method

A total of 34 patients with isolated liver metastasis from ocular melanoma underwent IHP. An overall survival comparison was made using data retrieved from the National Patient Register managed by the Swedish National Board of Health and Welfare.

Results

An overall radiological response was seen in 68 % of the patients, with 12 % having a complete response. Time to local progression was 7 months; 68 % of the patients developed extrahepatic metastases after a median of 13 months, and the median overall survival was 24 months. There was a significant survival advantage of 14 months (p = 0.029) when comparing these patients with a control group consisting of the longest surviving patients in Sweden with uveal melanoma liver metastases not treated with IHP.

Conclusions

IHP is a treatment option with a high response rate and a potential survival benefit of more than 1 year. IHP should be considered an option in the treatment of uveal melanoma metastases. A randomized trial comparing IHP and best alternative care will start during 2013 (the SCANDIUM trial, ClinicalTrials.gov identifier NCT01785316).

Reference

  1. 1.
    Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005;123:1639–43.PubMedCrossRefGoogle Scholar
  2. 2.
    Mariani P, Piperno-Neumann S, Servois V, Berry MG, Dorval T, Plancher C, et al. Surgical management of liver metastases from uveal melanoma: 16 years’ experience at the Institut Curie. Eur J Surg Oncol. 2009;35:1192–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Leyvraz S, Suciu S, Piperno-Neumann S, Baurain J.-F, Zdzienicki M, Testori A, et al. Randomized phase III trial of intravenous (IV) versus hepatic intra-arterial (HIA) fotemustine in patients with liver metastases from uveal melanoma: final results of the EORTC 18021 study. J Clin Oncol. 2012;30(15 suppl):8532.Google Scholar
  4. 4.
    Sharma KV, Gould JE, Harbour JW, Linette GP, Pilgram TK, Dayani PN, et al. Hepatic arterial chemoembolization for management of metastatic melanoma. AJR Am J Roentgenol. 2008;190:99–104.PubMedCrossRefGoogle Scholar
  5. 5.
    Ausman RK, Aust JB. Isolated perfusion of the liver with HN2. Surg Forum. 1960;10:77–9.PubMedGoogle Scholar
  6. 6.
    Rizell M, Mattson J, Cahlin C, Hafstrom L, Lindner P, Olausson M. Isolated hepatic perfusion for liver metastases of malignant melanoma. Melanoma Res. 2008;18:120–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRefGoogle Scholar
  8. 8.
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.PubMedCrossRefGoogle Scholar
  9. 9.
    Duh EJ, Schachat AP, Albert DM, Patel SM. Long-term survival in a patient with uveal melanoma and liver metastasis. Arch Ophthalmol. 2004;122:285–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. A phase I–II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2000;6:3062–70.PubMedGoogle Scholar
  11. 11.
    Alexander HR, Jr., Libutti SK, Pingpank JF, Steinberg SM, Bartlett DL, Helsabeck C, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2003;9:6343–9.PubMedGoogle Scholar
  12. 12.
    Noter SL, Rothbarth J, Pijl ME, Keunen JE, Hartgrink HH, Tijl FG, et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res. 2004;14:67–72.PubMedCrossRefGoogle Scholar
  13. 13.
    van Iersel LB, Hoekman EJ, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, et al. Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases. Ann Surg Oncol. 2008;15:1891–8.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Pingpank JF, Hughes MS, Alexander HR, Faries MB, Zager JS, Royal RE, et al. A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. J Clin Oncol. 2010;28(18 suppl):LBA8512.Google Scholar
  15. 15.
    Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother. 2012;61:41–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:782–9.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • R. Olofsson
    • 1
  • C. Cahlin
    • 2
  • C. All-Ericsson
    • 3
  • F. Hashimi
    • 4
  • J. Mattsson
    • 1
  • M. Rizell
    • 2
  • P. Lindnér
    • 2
  1. 1.Department of Surgery, Institute of Clinical SciencesSahlgrenska Academy at University of Gothenburg, Sahlgrenska University HospitalGöteborgSweden
  2. 2.Transplant Institute, Institute of Clinical SciencesSahlgrenska Academy at University of Gothenburg, Sahlgrenska University HospitalGöteborgSweden
  3. 3.Department of Clinical NeuroscienceKarolinska InstitutetStockholmSweden
  4. 4.Department of RadiologySahlgrenska University HospitalGöteborgSweden

Personalised recommendations